Pär-Ola Mannefred has an MBA from the School of Economics in Gothenburg. Contractor and active in own investment activities. Former CEO and co-owner of AB Högkullen (publ) and Residenset AB. He is also a board member of Johanneberg Science Park AB.

Position: Chairman of the Board

Elected: 2019

Year of birth: 1961

Holdings: 194 448 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Magnus he has been active in the field of business development at AstraZeneca since 2006. He has also been responsible for the Business Development group at Astra’s site in Gothenburg and participated in a large number of licensing and other types of transactions with both big pharma and small biotech. Since 2014, Magnus is leading AZ BioVentureHub AB, a commitment to strengthen the national development of start-up Life Science companies.

Position: Board Member

Elected: 2018

Year of birth: 1964

Holdings: 0 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Mr Robert Marchesani is currently principal at Proventus Health Solutions, LLC and an adjunct faculty member and executive career mentor at Butler University, Lacy School of Business in Indianapolis, Indiana. At Proventus, he serves as a consultant to oncology companies to incorporate prescriber, patient and payer insights throughout drug development and commercialization. Prior to joining Proventus, Mr. Marchesani spent more than 25 years at Eli Lilly and Company where he led the global branding, marketing and launch of a number of cancer therapeutics including, ALIMTA® (pemetrexed), Gemzar® (gemcitabine) and Verzenio™ (abemaciclib). Mr. Marchesani received his Bachelor of Arts degree in journalism and public relations from Indiana University of Pennsylvania and Masters of Business Administration with a concentration in marketing from the University of Indianapolis.

Position: Board Member

Elected: 2019 (2018 as an advisor)

Year of birth: 1961

Holdings: 5 000 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Anna Belfrage is a graduate economist (MBA) from Lund University. Previous Chief Financial Officer (CFO) for Södra Skogsägarna with responsibility also for purchasing and IT, formerly acting CEO of Beijer Electronics and CFO of ABS Group in Cardo Group. Also various roles within companies such as Dresser Wayne Fueling Systems, Obducat, Lund Eastern Energy, Åkerlund & Rausing and Serneke AB. Other assignments: Board member Note AB, Mycronic AB and Elopak AS.

Position: Board Member

Elected: 2019

Year of birth: 1962

Holdings: 5 250 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Dr. Alain Herrera, MD, PhD is an oncologist / hematologist that has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation.

Aram is CEO and member of the Executive Board of Noxxon Pharma, Germany. He brings over twenty years’ experience in the biotechnology industry. Aram has held leading positions in biotech companies such as C10 Pharma, Norway, Novexel and Exonhit Therapeutics, France with work on raising capital in listed companies and negotiating license and commercial sales agreements with leading pharmaceutical companies such as Roche, Merck & Co and AstraZeneca. He has a PhD in Biology from the University of California-San Diego, USA and an MBA from INSEAD, France.

Position: Board Member

Elected: 2020

Year of birth: 1969

Holdings: 0 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Paula´s skillset spans global commercialization planning, pre-launch preparation, major launch initiatives for first-in-class agents, and patient advocacy. She has been involved in introducing and supporting brands like Imbruvica (ibrutinib), Glivec/Gleevec (imatinib), Aranesp (darbopoetin), Camptosar (irinotecan), and Vectibix (panitumumab). In addition, Paula has held top-tier positions, as well as consulted, for major companies including Pharmacia (Pfizer), Novartis, Amgen, Proteolix (Onyx), Dendreon, Incyte, and Pharmacyclics, among others. Most recently Paula was Chief Commercial Officer at Oncopeptides AB.

Position: Board Member

Elected: 2018

Year of birth: 1958

Holdings: 0 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of June 30, 2021.

Lennart has negotiation experience from several of Swedish industry’s largest corporate deals, including Volvo’s sale of Volvo Cars, the acquisition of Renault and Mack Trucks and Stena Sessan’s sale of the shares in the pharmaceutical company Meda. Former Deputy CEO of the Volvo Group, CEO of Volvo Cars, Chairman of Skandia, 6 AP Fonden, Stena AB, Deputy Chairman of Chalmers Stiftelse, Board member of AGA, Atlas Copco, Bilia, Svenskt Näringsliv, Volvo Trucks, Volvo Construction Equipment, Orkla, Stena Metall and Stena Sessan AB. Lennart has a graduate Master of Business Administration from the Gothenburg School of Economics.

Position: Board member

Elected: 2021

Year of birth: 1941

Holdings: 953 750 shares*

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes